<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004584" GROUP_ID="STROKE" ID="297202100313052409" MERGED_FROM="" MODIFIED="2008-07-10 11:39:49 +0200" MODIFIED_BY="Hazel Fraser" REVIEW_NO="" REVMAN_SUB_VERSION="5.0.14" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2008-07-10 11:39:49 +0200" MODIFIED_BY="Hazel Fraser">
<TITLE>Tongxinluo capsule for acute stroke</TITLE>
<CONTACT MODIFIED="2008-07-10 11:39:49 +0200" MODIFIED_BY="Hazel Fraser"><PERSON ID="12346" ROLE="AUTHOR"><PREFIX>A/Prof</PREFIX><FIRST_NAME>Taixiang</FIRST_NAME><LAST_NAME>Wu</LAST_NAME><POSITION>Associate Professor</POSITION><EMAIL_1>txwutx@hotmail.com</EMAIL_1><EMAIL_2>txwutx@public.cd.sc.cn</EMAIL_2><ADDRESS><DEPARTMENT>Chinese Cochrane Centre, Chinese EBM Centre</DEPARTMENT><ORGANISATION>West China Hospital, Sichuan University</ORGANISATION><ADDRESS_1>No. 37, Guo Xue Xiang</ADDRESS_1><CITY>Chengdu</CITY><ZIP>610041</ZIP><REGION>Sichuan</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 28 8542 2081</PHONE_1><PHONE_2>+86 28 8517 6330</PHONE_2><FAX_1>+86 28 8554 2774</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-07-10 11:39:49 +0200" MODIFIED_BY="Hazel Fraser"><PERSON ID="79BE612482E26AA2007D5B6E42FF02AC" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Qi</FIRST_NAME><LAST_NAME>Zhuo</LAST_NAME><SUFFIX>MSc</SUFFIX><EMAIL_1>dexterzq_83@163.com</EMAIL_1><ADDRESS><DEPARTMENT>West China Hospital</DEPARTMENT><ORGANISATION>Sichuan University</ORGANISATION><ADDRESS_1>No. 37, Guo Xue Xiang</ADDRESS_1><CITY>Chengdu</CITY><ZIP>610041</ZIP><REGION>Sichuan</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 28 13880626965</PHONE_1><FAX_1>+86 28 85422253</FAX_1></ADDRESS></PERSON><PERSON ID="27A0884182E26AA200CD32E5EA41A307" ROLE="AUTHOR"><PREFIX>Miss</PREFIX><FIRST_NAME>Xunzhe</FIRST_NAME><LAST_NAME>Yang</LAST_NAME><SUFFIX>MSc</SUFFIX><EMAIL_1>celine23@163.com</EMAIL_1><ADDRESS><DEPARTMENT>West China Hospital</DEPARTMENT><ORGANISATION>Sichuan University</ORGANISATION><ADDRESS_1>No. 37, Guo Xue Xiang</ADDRESS_1><CITY>Chengdu</CITY><ZIP>610041</ZIP><REGION>Sichuan</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 28 13982278614</PHONE_1></ADDRESS></PERSON><PERSON ID="12346" ROLE="AUTHOR"><PREFIX>A/Prof</PREFIX><FIRST_NAME>Taixiang</FIRST_NAME><LAST_NAME>Wu</LAST_NAME><POSITION>Associate Professor</POSITION><EMAIL_1>txwutx@hotmail.com</EMAIL_1><EMAIL_2>txwutx@public.cd.sc.cn</EMAIL_2><ADDRESS><DEPARTMENT>Chinese Cochrane Centre, Chinese EBM Centre</DEPARTMENT><ORGANISATION>West China Hospital, Sichuan University</ORGANISATION><ADDRESS_1>No. 37, Guo Xue Xiang</ADDRESS_1><CITY>Chengdu</CITY><ZIP>610041</ZIP><REGION>Sichuan</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 28 8542 2081</PHONE_1><PHONE_2>+86 28 8517 6330</PHONE_2><FAX_1>+86 28 8554 2774</FAX_1></ADDRESS></PERSON><PERSON ID="12832" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Guanjian</FIRST_NAME><LAST_NAME>Liu</LAST_NAME><POSITION>Associate Professor</POSITION><EMAIL_1>ceuliu@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Chinese Cochrane Centre, Chinese EBM Centre</DEPARTMENT><ORGANISATION>West China Hospital, Sichuan University</ORGANISATION><ADDRESS_1>No. 37 Guo Xue Xiang</ADDRESS_1><CITY>Chengdu</CITY><ZIP>610041</ZIP><REGION>Sichuan</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 28 8542 2081</PHONE_1><FAX_1>+86 28 8542 2253</FAX_1></ADDRESS></PERSON><PERSON ID="12298" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Likun</FIRST_NAME><LAST_NAME>Zhou</LAST_NAME><POSITION>MSc student</POSITION><EMAIL_1>zhoubaling123@163.com</EMAIL_1><EMAIL_2>zhoubaling123@chinaren.com</EMAIL_2><ADDRESS><DEPARTMENT>Clinical Epidemiology</DEPARTMENT><ORGANISATION>West China Hospital of Sichuan University</ORGANISATION><ADDRESS_1>No.17, Ren Min Nan Lu</ADDRESS_1><CITY>Chengdu</CITY><ZIP>610041</ZIP><REGION>Sichuan Province</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 28 8542 2082</PHONE_1><FAX_1>+86 28 8554 2774</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-06-18 11:55:33 +0100" MODIFIED_BY="Hazel Fraser">
<UP_TO_DATE>
<DATE DAY="19" MONTH="3" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="24" MONTH="1" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="22" MONTH="3" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2004"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2004"/>
</DATES>
<WHATS_NEW MODIFIED="2008-05-30 14:05:37 +0100" MODIFIED_BY="Hazel Fraser">
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="28" MONTH="3" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-03-28 10:47:09 +0000" MODIFIED_BY="Hazel Fraser"/>
<SOURCES_OF_SUPPORT MODIFIED="2008-05-30 14:48:08 +0100" MODIFIED_BY="Hazel Fraser">
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Chinese Cochrane Centre, West China Hospital of Sichuan University</NAME>
<COUNTRY CODE="CN">China</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2008-05-30 14:48:08 +0100" MODIFIED_BY="Hazel Fraser">
<SOURCE MODIFIED="2008-05-30 14:48:08 +0100" MODIFIED_BY="Hazel Fraser">
<NAME>Chinese Medical Board of New York</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-07-04 14:55:27 +0100" MODIFIED_BY="Hazel Fraser">
<SUMMARY MODIFIED="2008-06-18 13:14:48 +0100" MODIFIED_BY="Hazel Fraser">
<TITLE MODIFIED="2008-05-30 14:06:21 +0100" MODIFIED_BY="Hazel Fraser">Tongxinluo capsule for acute stroke</TITLE>
<SUMMARY_BODY MODIFIED="2008-06-18 13:14:48 +0100" MODIFIED_BY="Hazel Fraser">
<P>Traditional Chinese medicine is often used to treat patients with acute ischaemic stroke. The authors undertook a systematic review of the potential benefits and safety of tongxinluo capsule used for the treatment of patients with acute ischaemic stroke. Two relevant studies with a total of 232 participants were identified, but they did not provide reliable evidence about the effects of this treatment. Larger-scale high quality randomised controlled trials (RCTs) are needed to determine the effects of tongxinluo capsule in patients with stroke.
<BR/>

</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-06-18 13:59:10 +0100" MODIFIED_BY="Hazel Fraser">
<ABS_BACKGROUND MODIFIED="2008-06-18 13:10:25 +0100" MODIFIED_BY="Hazel Fraser">
<P>Tongxinluo capsules are a compound of Chinese traditional medicine which contain substances that are thought to have vasodilatory, antiplatelet, anticoagulant, thrombolytic and even lipid-lowering properties, and therefore may improve outcome after acute ischaemic stroke. To date the evidence of its effect has not been systematically reviewed, making it difficult to derive robust conclusions about its actual benefits, and indeed, possible harms.<BR/>
</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-06-18 13:10:42 +0100" MODIFIED_BY="Hazel Fraser">
<P>To assess the effectiveness and possible harms of tongxinluo capsule for acute cerebral infarction compared with control.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-06-18 13:12:28 +0100" MODIFIED_BY="Hazel Fraser">
<P>We searched the Cochrane Stroke Group trials register (last searched on 24 January 2008) the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I>, Issue 4, 2007), MEDLINE (1995 to 2006), EMBASE (1995 to 2006), China National Knowledge Infrastructure (CNKI, 1994 to 2006), CBM (Chinese Biomedical Database) (1995 to 2006), Current Controlled Trials (www.controlled-trials.com), National Research Register (http://www.update-software.com/national/). We handsearched 30 journals (1995 to 2006), and contacted drug companies and the principal of included trials.<BR/>
</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2008-06-18 13:13:54 +0100" MODIFIED_BY="Hazel Fraser">
<P>Randomised controlled trials comparing tongxinluo with placebo or open control (or tongxinluo plus standard therapy versus standard therapy alone) in people with definite acute stroke. We excluded trials if they sought to recruit patients with transient ischaemic attacks (TIA), intracerebral haemorrhage, heart failure, or renal failure.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-06-18 13:59:10 +0100" MODIFIED_BY="Hazel Fraser">
<P>Two review authors extracted data and assessed trial quality.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-06-18 13:13:14 +0100" MODIFIED_BY="Hazel Fraser">
<P>Only two poor quality studies with a total of 232 participants were included in this review. Neither study reported any of our pre-specified outcomes, so no reliable estimate of the effect of treatment on major clinical outcomes could be obtained.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-06-18 13:14:03 +0100" MODIFIED_BY="Hazel Fraser">
<P>It was not possible to reliably determine whether tongxinluo has a favourable or unfavourable effect in acute ischaemic stroke. High quality trials are required to assess the efficacy and safety of tongxinluo capsule for acute ischaemic stroke.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-07-04 14:55:27 +0100" MODIFIED_BY="Hazel Fraser">
<BACKGROUND MODIFIED="2008-06-18 13:31:32 +0100" MODIFIED_BY="Hazel Fraser">
<P>There are two main types of stroke: ischaemic (if an artery to the brain is blocked), or haemorrhagic (if an artery to the brain bursts and bleeding occurs) (<LINK REF="REF-Stanford-1999" TYPE="REFERENCE">Stanford 1999</LINK>).</P>
<P>When the lining of a blood vessel (the endothelium) is damaged blood platelets adhere to it and may provoke the local formation of a clot (or thrombus) which blocks the vessel. This will occur more readily if the blood shows an increased propensity for clotting. Clot dissolving (or thrombolytic) drugs may restore blood supply to the brain after a stroke, but may also cause serious bleeding in the brain (<LINK REF="REF-Wardlaw-2003" TYPE="REFERENCE">Wardlaw 2003</LINK>). Antiplatelet therapy, with drugs like aspirin, has been shown to reduce the risk of recurrent stroke, myocardial infarction and vascular death in patients with a history of stroke or transient ischaemic attack by about 15% to 20% (<LINK REF="REF-Algra-1996" TYPE="REFERENCE">Algra 1996</LINK>; <LINK REF="REF-APT-1994" TYPE="REFERENCE">APT 1994</LINK>).</P>
<P>There are over one million new strokes each year in the European Union and the USA (<LINK REF="REF-Bamford-1990" TYPE="REFERENCE">Bamford 1990</LINK>; <LINK REF="REF-Broderick-1989" TYPE="REFERENCE">Broderick 1989</LINK>; <LINK REF="REF-Homer-1987" TYPE="REFERENCE">Homer 1987</LINK>), of which 85% are ischaemic (<LINK REF="REF-Bamford-1990" TYPE="REFERENCE">Bamford 1990</LINK>). It is estimated that there will be 8.5 million patients with acute ischaemic stroke in these countries over the next decade and of these about one and a half million will die within six months of stroke onset (<LINK REF="REF-Sandercock-1992" TYPE="REFERENCE">Sandercock 1992</LINK>). Of those who survive, about one third will depend on other people for help with their activities of daily living (<LINK REF="REF-IST-Pilot-1996" TYPE="REFERENCE">IST Pilot 1996</LINK>).</P>
<P>Tongxinluo capsule has properties that might be effective in acute stroke. It is a new drug (clinical study was started in 1995) for cardio-cerebral vascular diseases on the national essential drug list of China, and has the second-class award of the National Science and Technology Development of China 2001 (<LINK REF="REF-Editor-2002" TYPE="REFERENCE">Editor 2002</LINK>). The composition of Tongxinluo capsule includes <I>Radi Ginseng</I>, <I>Scorpio</I>, <I>Hirudo</I>, <I>Eupolyphaga seu Steleophage</I>, <I>Scolopendra</I>, <I>Periostracum Cicadae</I>, <I>Radix Paeoniae Rubra</I>, and <I>Borneolum Syntheticum</I> (<LINK REF="REF-Editor-2002" TYPE="REFERENCE">Editor 2002</LINK>; <LINK REF="REF-Liu-1997" TYPE="REFERENCE">Liu 1997</LINK>; <LINK REF="STD-Wu-2001" TYPE="STUDY">Wu 2001</LINK>). These materials are powdered and prepared as capsules which contain 0.38g of mixture (<LINK REF="STD-Wu-2001" TYPE="STUDY">Wu 2001</LINK>). Pharmacological studies showed that <I>Radix Ginseng</I> dilates blood vessels, has anticoagulant effects, and inhibits platelet adhesion reaction (<LINK REF="REF-Xu-1988a" TYPE="REFERENCE">Xu 1988a</LINK>). <I>Hirudo</I>'s action includes anticoagulation (<LINK REF="REF-Ou-1987" TYPE="REFERENCE">Ou 1987</LINK>), thrombolysis, it reduces viscosity of whole blood (<LINK REF="REF-Xu-1988b" TYPE="REFERENCE">Xu 1988b</LINK>), reduces blood cholesterol, and has atherosclerotic actions (<LINK REF="REF-Wu-1994" TYPE="REFERENCE">Wu 1994</LINK>). <I>Periostracum Cicadae</I> acts as an anticonvulsant and slows heart rate down significantly (<LINK REF="REF-Pharmacology-1960" TYPE="REFERENCE">Pharmacology 1960</LINK>). <I>Scolopendra</I> extraction strengthens cardiac contractility, decreases blood pressure, and increases blood vessel perfusion flow (<LINK REF="REF-Chen-1985" TYPE="REFERENCE">Chen 1985</LINK>). <I>Radix Paeoniae Rubra</I> has anticoagulant and antithrombotic effects (<LINK REF="REF-Deng-1991" TYPE="REFERENCE">Deng 1991</LINK>; <LINK REF="REF-Lu-1983" TYPE="REFERENCE">Lu 1983</LINK>). <I>Eupolyphaga seu Steleophage</I> increases cardiac output and improves tolerance of hypoxia (<LINK REF="REF-Nong-1989" TYPE="REFERENCE">Nong 1989</LINK>; <LINK REF="REF-Yang-1989" TYPE="REFERENCE">Yang 1989</LINK>). The actions of <I>Borneolum Syntheticum</I> are analgesia and sedation (<LINK REF="STD-Wu-2001" TYPE="STUDY">Wu 2001</LINK>). <I>Scorpio</I> is used in traditional Chinese medicine mainly for hypertension, apoplexy, arteriosclerosis, some nervous system diseases, and various infections (<LINK REF="REF-Wang-1998" TYPE="REFERENCE">Wang 1998</LINK>). These components of tongxinluo and their pharmacological actions are listed in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> with their Latin and common names. </P>
<P>Some completed research (Fan 2001; <LINK REF="STD-Xu-2001" TYPE="STUDY">Xu 2001</LINK>) suggested that the capsule might have effects on acute cerebral infarction, but this research has not been systematically reviewed.</P>
<P>In light of this incomplete evidence and the possibility of side effects, a systematic review of controlled trials of tongxinluo capsule is needed.<BR/>
</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2008-06-18 13:25:00 +0100" MODIFIED_BY="Hazel Fraser">
<P>To assess the effect (harms and benefits) of tongxinluo capsule for acute cerebral infarction compared with control.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-07-04 14:55:27 +0100" MODIFIED_BY="Hazel Fraser">
<SELECTION_CRITERIA MODIFIED="2008-06-18 13:33:43 +0100" MODIFIED_BY="Hazel Fraser">
<CRIT_STUDIES MODIFIED="2008-06-18 13:25:12 +0100" MODIFIED_BY="Hazel Fraser">
<P>We considered unconfounded randomised controlled trials comparing tongxinluo with placebo or open control (or tongxinluo plus standard therapy versus standard therapy alone).</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-06-18 13:32:46 +0100" MODIFIED_BY="Hazel Fraser">
<P>Participants were male or female of any age or ethnic origin with acute cerebral infarction in any vascular territory confirmed by computerised tomography (CT) or magnetic resonance imaging (MRI) brain scan. We excluded trials that sought to recruit patients with transient ischaemic attacks (TIA), intracerebral haemorrhage, heart failure, or renal failure.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-06-18 13:33:02 +0100" MODIFIED_BY="Hazel Fraser">
<P>Tongxinluo capsule compared with placebo or no intervention (or tongxinluo plus standard treatment versus standard treatment alone).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-06-18 13:33:43 +0100" MODIFIED_BY="Hazel Fraser">
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome measures</HEADING>
<P>(1) Death from any cause during the scheduled follow-up period.<BR/>(2) The proportion of participants who were dead or dependent on others for activities of daily living at the end of the scheduled follow-up period.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcome measures</HEADING>
<P>(1) Neurological impairment at the end of follow up.<BR/>(2) Death during scheduled treatment period.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse events</HEADING>
<P>(1) Bleeding, nausea, vomiting, abdominal pain, diarrhoea, allergic action, or other serious adverse event caused by tongxinluo.<BR/>(2) Frequency of other complications such as pneumonia, coagulopathy or other serious adverse events during treatment and follow-up period.</P>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-07-01 17:14:33 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>See</I>: 'Specialized Register' section in <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/stroke/frame.html">Cochrane Stroke Group</A>
</P>
<P>We conducted a comprehensive and exhaustive search in an attempt to identify all relevant studies in all languages, published or unpublished.</P>
<SUBSECTION>
<HEADING LEVEL="3">Electronic searches</HEADING>
<P>We searched the Cochrane Stroke Group Trials Register, which was last searched by the Review Group Co-ordinator on 24 January 2008. In addition, we searched the following electronic databases and trials and research registers in an attempt to identify published, unpublished and ongoing studies.</P>
<UL>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> Issue 4, 2007)</LI>
<LI>MEDLINE (1995 to 2006)</LI>
<LI>EMBASE (1995 to 2006)</LI>
<LI>China National Knowledge Infrastructure (CNKI) (1994 to 2006)</LI>
<LI>Chinese Biomedical Database (CBM) (1995 to 2006)</LI>
<LI>Current Controlled Trials (www.controlled-trials.com)</LI>
<LI>National Research Register (http://www.update-software.com/national/)</LI>
</UL>
<P>The following text word search was used for all databases:</P>
<P>Tongxinluo or Tong xin luo or Tong-xin-luo or TXLC or TXL</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Handsearches</HEADING>
<P>We have handsearched the following Chinese traditional medicine journals (1995 to 2006):</P>
<UL>
<LI>China Journal of Basic Medicine in Traditional Chinese Medicine;</LI>
<LI>Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care;</LI>
<LI>Chinese Journal of Traditional &amp; Western Medicine;</LI>
<LI>Chinese Traditional Patent Medicine;</LI>
<LI>Chinese Traditional Patent Medicine Research;</LI>
<LI>Chinese Traditional and Herbal Drugs;</LI>
<LI>Chinese Pharmaceutical Abstracts;</LI>
<LI>Forum on Traditional Chinese Medicine;</LI>
<LI>Fujian Journal of Traditional Chinese Medicine;</LI>
<LI>Guang Ming Zhong Yi Journal of Traditional Chinese Medicine;</LI>
<LI>Gansu Journal of Traditional Chinese Medicine;</LI>
<LI>Guangxi Journal of Traditional Chinese Medicine;</LI>
<LI>Guangdong Journal of Traditional Chinese Medicine;</LI>
<LI>Hebei Integrated Traditional and Western Medicine;</LI>
<LI>Hebei Journal of Traditional Chinese Medicine;</LI>
<LI>Heilongjang Journal of Traditional Chinese Medicine;</LI>
<LI>Henan Journal of Traditional Chinese Medicine and Pharmacy;</LI>
<LI>Henan Journal of Traditional Chinese Medicine;</LI>
<LI>Information on Traditional Chinese Medicine;</LI>
<LI>Jiangxi Journal of Traditional Chinese Medicine;</LI>
<LI>Jilin Journal of Traditional Chinese Medicine;</LI>
<LI>Journal of Chinese Medicinal Materials;</LI>
<LI>Journal of Emergency in Traditional Chinese Medicine;</LI>
<LI>Journal of HeNan College of Traditional Chinese Medicine;</LI>
<LI>Journal of Practical Chinese Traditional Internal Medicine;</LI>
<LI>Modern Traditional Chinese Medicine;</LI>
<LI>Neimongol Journal of Traditional Chinese Medicine;</LI>
<LI>Pharmacology and Clinics of Chinese Materia Medica;</LI>
<LI>Shenzhen Journal of Integrated Traditional and Western Medicine;</LI>
<LI>Xinjiang Journal of Traditional Chinese Medicine.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Other search strategies</HEADING>
<P>In an effort to identify further published and unpublished trials, we contacted relevant organizations (including the World Health Organization), companies manufacturing tongxinluo, and researchers and colleagues working in the field. The reference lists of all relevant publications have been examined.</P>
</SUBSECTION>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-07-04 14:55:27 +0100" MODIFIED_BY="Hazel Fraser">
<SUBSECTION>
<HEADING LEVEL="3">Trials selection</HEADING>
<P>To determine the studies to be assessed further, we scanned the titles, abstract sections and keywords of every record retrieved. We retrieved the full article for further assessment if the information given suggested that the study:<BR/>(1) included participants with acute cerebral infarction;<BR/>(2) compared tongxinluo with any control;<BR/>(3) assessed one or more relevant clinical outcome measure;<BR/>(4) used random allocation to the comparison groups.<BR/>
<BR/>There were no disagreements between review authors.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality assessment of trials</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Assessment of risk of bias in included trials</HEADING>
<P>Two authors will independently assess risk of bias using the following criteria that are described in the Cochrane Handbook for Systematic Reviews of Interventions 5.0.0 (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>) and <LINK REF="REF-Wu-2007" TYPE="REFERENCE">
Wu 2007
</LINK>. We will assess the following characteristics.</P>
<SUBSECTION>
<HEADING LEVEL="5">Randomisation process: assessment of selection bias</HEADING>
<P>A - adequate sequence generation is reported using one of the following approaches: random number tables or computer-generated random numbers. Coin tossing or shuffling used for generating the allocation sequence before the trial started will be considered eligible and with a low risk of selection bias.<BR/>B - does not specify one of the adequate methods outlined in A but only mentioned 'random' and will be considered at moderate risk of selection bias.<BR/>C - other methods of allocation, for example, quasi-randomisation, that appeared to be at high risk of bias and will be excluded.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Allocation concealment process: assessment of selection bias</HEADING>
<P>A - adequate measures to conceal allocation defined as when the person enrolling participants cannot forsee allocation assignment, for example, central randomisation, sealed opaque envelopes, the allocation sequence is held in a locked computer, or another description that describes good concealment will be considered at low risk of selection bias.<BR/>B - unclear: concealed trials in which the author does not report the method of allocation concealment at all will be considered at moderate risk of selection bias.<BR/>C - inadequately-concealed allocation that does not fall into one of the categories in A.<BR/>D - does not conceal allocation.</P>
<P>C and D will be considered at high risk of selection bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Level of blinding: assessment of performance bias and detection bias</HEADING>
<P>A - double blinding: participants and outcome assessors were masked and will be considered at low risk of both performance and detection bias.<BR/>B - single blinding for outcome assessors will be considered at moderate risk of both performance and detection bias. If participants were single blinded but not the outcome assessors, it will be considered at high risk of detection bias.<BR/>C - non-blinding will be considered as a high risk for both performance and detection bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Drop out, withdrawal, loss to follow up: assessment of potential attrition bias</HEADING>
<P>A - low risk of attrition bias: trials where an intention-to-treat analysis is possible and few drop outs or losses to follow up are noted.<BR/>B - moderate risk of attrition bias: trials which reported the rate of exclusions was about 10% whatever intention-to-treat analysis was used.<BR/>C - high risk of attrition bias: the rate of exclusion was at least 15%, or wide differences in exclusions between groups whatever the intention-to-treat analysis was used.</P>
<P>Based on these criteria, we broadly subdivided studies into the following three categories:<BR/>A - all quality criteria met: low risk of bias;<BR/>B - one or more of the quality criteria only partly met: moderate risk of bias;<BR/>C - one or more criteria not met: high risk of bias.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data extraction</HEADING>
<P>Two review authors (ZQ and WT) independently extracted data using a piloted data extraction form. We extracted data on study characteristics including methods, participants, interventions, and outcomes. We resolved any disagreements by referring to the trial report and through discussion.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data analysis</HEADING>
<P>We analysed the data using the Review Manager software RevMan 5. We summarised dichotomous data as relative risk (RR). There were no continuous data; in future, we would expressed such data as mean difference (MD). We used 95% confidence intervals throughout. We have listed non-randomised controlled studies but these have not been discussed further. We did not perform subgroup analyses because of clinical heterogeneity of the only two studies included.</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-07-02 13:20:48 +0100" MODIFIED_BY="Hazel Fraser">
<STUDY_DESCRIPTION MODIFIED="2008-07-01 17:19:05 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>See</I> <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>
</P>
<SUBSECTION>
<HEADING LEVEL="3">Studies identified</HEADING>
<P>After reading titles and abstracts, we retained 29 studies for advanced assessment. Of these, we excluded six studies because they were confounded studies without proper control (<LINK REF="STD-Liu-2001" TYPE="STUDY">Liu 2001</LINK>; <LINK REF="STD-Liu-2001b" TYPE="STUDY">Liu 2001b</LINK>; <LINK REF="STD-Liu-2001c" TYPE="STUDY">Liu 2001c</LINK>; <LINK REF="STD-Lu-2001" TYPE="STUDY">Lu 2001</LINK>; <LINK REF="STD-Wang-2006b" TYPE="STUDY">Wang 2006b</LINK>; <LINK REF="STD-Zhang-2001" TYPE="STUDY">Zhang 2001</LINK>). We excluded four other studies because they were retrospective trials with no research protocol (<LINK REF="STD-Ding-2003" TYPE="STUDY">Ding 2003</LINK>; <LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>; <LINK REF="STD-Xu-2003" TYPE="STUDY">Xu 2003</LINK>; <LINK REF="STD-Zhang-2002" TYPE="STUDY">Zhang 2002</LINK>), another six because they were quasi-randomised trials with no blinding (<LINK REF="STD-Gu-2004" TYPE="STUDY">Gu 2004</LINK>; <LINK REF="STD-Han-2006" TYPE="STUDY">Han 2006</LINK>; <LINK REF="STD-Hu-2002" TYPE="STUDY">Hu 2002</LINK>; <LINK REF="STD-Yang-2001" TYPE="STUDY">Yang 2001</LINK>; <LINK REF="STD-Zhou-2005" TYPE="STUDY">Zhou 2005</LINK>; <LINK REF="STD-Zhou-2004" TYPE="STUDY">Zhou 2004</LINK>), and another four because they were non-RCTs (<LINK REF="STD-Jia-2001" TYPE="STUDY">Jia 2001</LINK>; <LINK REF="STD-Lu-2002" TYPE="STUDY">Lu 2002</LINK>; <LINK REF="STD-Xu-2001" TYPE="STUDY">Xu 2001</LINK>; <LINK REF="STD-Xu-2001b" TYPE="STUDY">Xu 2001b</LINK>). The reasons for the other exclusions can be seen in <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>. Finally, we consider that only two trials (<LINK REF="STD-Ding-2004" TYPE="STUDY">Ding 2004</LINK>; <LINK REF="STD-Wang-2006" TYPE="STUDY">Wang 2006</LINK>), with a total of 120 and 112 participants respectively, fulfilled the defined inclusion criteria; however we were unable to contact the authors for more information.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Design of included studies</HEADING>
<P>Details of the characteristics of the included studies are shown in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>. The two included studies were of single centre, parallel design and had a control group. Both of them mentioned randomisation, but the specific randomisation procedure was unclear. For both of the two studies, individual participants formed the unit for allocation, and whether allocation concealment was used was unknown. Trial duration was two and four weeks respectively. Both the trials were conducted in China.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Participants in included studies</HEADING>
<P>The number of participants in the studies was 120 (<LINK REF="STD-Ding-2004" TYPE="STUDY">Ding 2004</LINK>) and 112 (<LINK REF="STD-Wang-2006" TYPE="STUDY">Wang 2006</LINK>), and all were diagnosed as cerebral infarction based on head MRI or CT, and in accordance with the diagnosis criteria formulated at the 4th Chinese National Symposium on Cerebrovascular Diseases. The age of participants ranged from 35 to 83 years with mean age about 62 years old. Baseline neurological impairment was mentioned as similar between the two groups although detailed data were unavailable.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Interventions in included studies</HEADING>
<P>One study (<LINK REF="STD-Ding-2004" TYPE="STUDY">Ding 2004</LINK>) compared routine treatment plus tongxinluo capsule to routine treatment (detailed data unavailable), the other study (<LINK REF="STD-Wang-2006" TYPE="STUDY">Wang 2006</LINK>) compared routine treatment (low molecular heparin, mannitol, citicoline, etc) plus tongxinluo capsule to routine treatment (low molecular heparin, mannitol, citicoline, etc).</P>
<P>Tongxinluo was given in the form of capsules and taken orally three times a day. Doses and duration of treatment however varied between the two studies: <LINK REF="STD-Ding-2004" TYPE="STUDY">Ding 2004</LINK> administered four capsules at a time for four weeks, while <LINK REF="STD-Wang-2006" TYPE="STUDY">Wang 2006</LINK> administered three capsules for two weeks.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcome measures of included studies</HEADING>
<P>Both of the two studies reported neurological impairment and daily living capability improvement based on Chinese national therapeutic effect evaluation criteria and the Modified Edinberg-Scandinavian stroke scale. No primary outcome measures were reported. Neither were adverse effects.</P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-06-18 14:24:05 +0100" MODIFIED_BY="Hazel Fraser">
<P>Both of the two included trials were of low quality (C). An overview of study quality can be found in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="3">Randomisation</HEADING>
<P>Both of the included studies mentioned randomisation, but neither of them described the method of randomisation in detail.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Allocation concealment</HEADING>
<P>Neither of the included studies mentioned allocation concealment. We tried to interview the authors of the studies by telephone for more detailed information but without success.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Blinding</HEADING>
<P>Neither of the two studies mentioned blinding.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Description of withdrawals and losses to follow up and intention-to-treat analysis</HEADING>
<P>Neither study mentioned withdrawals and losses to follow up, or performed intention-to-treat analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Similarity of comparison groups at baseline</HEADING>
<P>Both studies considered age and gender to be important factors and appeared to be balanced across the treatment and control groups, but no details were available. <LINK REF="STD-Wang-2006" TYPE="STUDY">Wang 2006</LINK> reported the duration of acute stroke.</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-07-02 13:20:48 +0100" MODIFIED_BY="Hazel Fraser">
<SUBSECTION>
<HEADING LEVEL="3">Primary outcome measures</HEADING>
<P>Neither study reported any primary outcome measures as defined.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcome measures</HEADING>
<P>Both studies reported neurological impairment and daily living capability improvement at the end of follow up based on Chinese National Therapeutic Effect Evaluation Criteria and the Modified Edinburgh-Scandinavian Stroke Scale.</P>
<P>
<LINK REF="STD-Ding-2004" TYPE="STUDY">Ding 2004</LINK> showed no significant difference between the two groups, and that tongxinluo was no better or worse at improving neurological impairment and daily living capability when comparing routine treatment plus tongxinluo capsule to routine treatment (RR 1.24, 95% CI 0.98 to1.56).<BR/>

<BR/>

<LINK REF="STD-Wang-2006" TYPE="STUDY">Wang 2006</LINK> showed that routine treatment (low molecular heparin, mannitol, citicoline, etc) plus tongxinluo capsule was better at improving neurological impairment and daily living capability than routine treatment (low molecular heparin, mannitol, citicoline, etc) alone (RR 1.79, 95% CI 1.35 to 2.36).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analysis</HEADING>
<P>The duration of follow up for the two studies was different; we were therefore unable to analyse the studies according to short or long-term follow up. It was the same for the subgroup analysis based on dosage.<BR/>
</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-06-18 15:31:47 +0100" MODIFIED_BY="Hazel Fraser">
<SUBSECTION>
<HEADING LEVEL="2">Limitations of included studies and the review</HEADING>
<P>This systematic review aimed to examine and compare the effectiveness of the traditional Chinese preparation tongxinluo alone and in combination with placebo or other routine treatment. However, only two studies which compared tongxinluo plus routine treatment with routine treatment have been included, both of which are of low quality. There was weak evidence from one trial of benefit on the non-standardised outcome improvement in impairment and daily living capability, but no overall estimate of effect could be obtained because of the marked clinical and statistical heterogeneity. Overall, studies of tongxinluo for acute ischaemic stroke lack sufficient power to provide reliable estimates of the effects.<BR/>
<BR/>(1) Both included studies focused on neurological impairment and daily living capability improvement only in a short treatment duration, but not on mortality. It has been pointed out that few trials of traditional Chinese medicine for stroke assess mortality as the primary outcome, and that reducing the rate of death from stroke should be the main objective of treatment (<LINK REF="REF-Wu-2007" TYPE="REFERENCE">Wu 2007</LINK>). Thus the follow-up duration should be much longer than the included studies.
<BR/>

<BR/>(2) Both the neurological impairment and daily living capability improvement are highly subjective outcomes rating the participants current state to their pre-treatment state. Particularly, they were not tested blindly, so there is a high risk of detection bias.<BR/>
<BR/>(3) Neither study found adverse effects in the use of tongxinluo. Due to the small sample size, safety is yet to be assessed.</P>
<P>(4) Publication bias may exist because only Chinese language publications were found and included.</P>
<P>(5) Among the papers that we retrieved for further details, the fact that the great majority were small sample clinical trials (less than 100 people) may limit the applicability of the systematic review. But due to various reasons, it is a fact that most if not all studies of traditional Chinese medicines were of a small sample size. There was no study that reported on the defined primary outcomes measures.</P>
<P>(6) Most of the trials claimed to be RCTs, but most of them failed to give adequate and convincing information about the methodological quality, and when we telephoned the trial authors about the method of randomisation they used, we found that many of them described the concept of randomisation incorrectly.</P>
<P>Meanwhile, both the included studies were of poor methodological quality and neither randomisation procedure nor blinding and allocation concealment were mentioned in the studies. This could lead to a high risk of both selection bias and detection bias. We were unable to contact the two authors at present. We will make further attempts to contact relevant authors for detailed information of allocation concealment and randomisation for an update of this review in the future.</P>
<P>(7) The administration of tongxinluo capsule lacks a standard regimen, therefore different studies used varying trial durations and dosage. This may have resulted in some clinical heterogeneity between studies, making it hard to perform any pooled analysis. Furthermore, the comparator treatment in some trials was probably sub-optimal. For example, <LINK REF="STD-Wang-2006" TYPE="STUDY">Wang 2006</LINK> only used low molecular heparin, mannitol, and citicoline in the control group. Consequently, tongxinluo may have shown a more beneficial effect in this particular trial.</P>
<P>(8) Neither of the included studies mentioned ethical issues or whether the participants gave informed consent.<BR/>
</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-06-18 15:32:45 +0100" MODIFIED_BY="Hazel Fraser">
<IMPLICATIONS_PRACTICE MODIFIED="2008-06-18 15:31:57 +0100" MODIFIED_BY="Hazel Fraser">
<P>We found insufficient evidence to support the routine use of tongxinluo for the treatment of acute stroke.<BR/>
</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-06-18 15:32:45 +0100" MODIFIED_BY="Hazel Fraser">
<P>More high quality randomised controlled trials, following the CONSORT criteria, are required for assessing the effects of tongxinluo, alone or in combination with placebo or routine standard treatment for acute ischaemic stroke. Relevant clinical events such as death and the proportion of participants who were dead or dependent on others for activities of daily living at the end of the scheduled follow-up period should be included in outcomes assessed in these studies, and adverse effects should be investigated to assess safety.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2008-06-18 15:33:21 +0100" MODIFIED_BY="Hazel Fraser">
<P>We thank Hazel Fraser, Review Group Co-ordinator of the Cochrane Stroke Group, and Graeme Hankey, Steff Lewis, Brenda Thomas, Lawrence Wong, Peter Sandercock and Richard Kay for their advice on writing the review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2008-06-18 14:00:09 +0100" MODIFIED_BY="Hazel Fraser">
<P>None known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-05-30 14:17:35 +0100" MODIFIED_BY="Hazel Fraser">
<P>Qi Zhuo and Xunzhe Yang: trials searching, quality assessment of trials, data extraction, data analysis, review development.<BR/>Taixiang Wu: protocol development, searching for data, data extraction, data analysis, review development.<BR/>Likun Zhou: protocol development.<BR/>Guanjian Liu: data analysis.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-07-04 14:24:52 +0100" MODIFIED_BY="Hazel Fraser">
<STUDIES MODIFIED="2008-07-02 13:19:29 +0100" MODIFIED_BY="Hazel Fraser">
<INCLUDED_STUDIES MODIFIED="2008-06-18 12:20:54 +0100" MODIFIED_BY="Hazel Fraser">
<STUDY DATA_SOURCE="PUB" ID="STD-Ding-2004" MODIFIED="2008-05-30 14:35:43 +0100" MODIFIED_BY="Hazel Fraser" NAME="Ding 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-05-30 14:35:43 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ding L, Du W</AU>
<TI>Therapeutic effect observation of Tongxinluo capsule for 68 cases of acute cerebral infarction</TI>
<SO>Journal of Traditional Chinese Medicine and Pharmacology</SO>
<YR>2004</YR>
<VL>32</VL>
<NO>2</NO>
<PG>31-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2006" MODIFIED="2008-06-18 12:20:54 +0100" MODIFIED_BY="Hazel Fraser" NAME="Wang 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-06-18 12:20:54 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang X</AU>
<TI>Therapeutic effect observation of Tongxinluo capsule for 56 cases of acute cerebral infarction</TI>
<SO>Chinese Journal of Practical Nervous Diseases</SO>
<YR>2006</YR>
<VL>9</VL>
<PG>72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-07-02 13:19:29 +0100" MODIFIED_BY="Hazel Fraser">
<STUDY DATA_SOURCE="PUB" ID="STD-Cai-2001" MODIFIED="2008-05-30 14:36:32 +0100" MODIFIED_BY="Hazel Fraser" NAME="Cai 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-05-30 14:36:32 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Cai DF, Ruan QW, Chen XQ, Shen SJ, Zhao G, Liu J</AU>
<TI>Research of tongxinluo capsule for acute stroke</TI>
<SO>Luobing theory of Chinese medicine and cardio-cerebral angiopathy</SO>
<YR>2001</YR>
<PG>290-1</PG>
<EN>1st</EN>
<ED>Wu YL</ED>
<PB>Chinese Science and Technical Publish House</PB>
<CY>Beijing</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2001" MODIFIED="2008-06-18 15:35:08 +0100" MODIFIED_BY="Hazel Fraser" NAME="Chen 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-06-18 15:35:08 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Chen ZH</AU>
<TI>The effect of Tongxinluo capsule for acute stroke</TI>
<SO>Luobing theory of Chinese medicine and cardio-cerebral angiopathy</SO>
<YR>2001</YR>
<PG>315</PG>
<EN>1st</EN>
<ED>Wu YL</ED>
<PB>Chinese Science and Technical Publish House</PB>
<CY>Beijing</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ding-2003" MODIFIED="2008-06-18 12:22:25 +0100" MODIFIED_BY="Hazel Fraser" NAME="Ding 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-06-18 12:22:25 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ding XJ, Xu YM, Liu L, Jiang XF, Liu XL, Luo ZM</AU>
<TI>Observation of the result of Tongxinluo capsule for the treatment acute cerebral infarction and analysis of its mechanism</TI>
<SO>West China Medical Journal</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>4</NO>
<PG>494-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fan--2001" MODIFIED="2008-06-18 12:22:40 +0100" MODIFIED_BY="Hazel Fraser" NAME="Fan  2001" YEAR="2001">
<REFERENCE MODIFIED="2008-06-18 12:22:40 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Fan WH, Zhang B</AU>
<TI>Clinical research of Tongxinluo capsule for acute stroke</TI>
<SO>Luobing theory of Chinese medicine and cardio-cerebral angiopathy</SO>
<YR>2001</YR>
<PG>273-6</PG>
<EN>1st</EN>
<ED>Wu YL</ED>
<PB>Chinese Science and Technical Publish House</PB>
<CY>Beijing</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gu-2004" MODIFIED="2008-06-18 12:23:03 +0100" MODIFIED_BY="Hazel Fraser" NAME="Gu 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-06-18 12:23:03 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gu YM, Zhu Y</AU>
<TI>Therapeutic effect observation of Tongxinluo capsule for cerebral infarction</TI>
<SO>Modern Journal of Integrated Traditional Chinese and Western Medicine</SO>
<YR>2004</YR>
<VL>13</VL>
<NO>2</NO>
<PG>178-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Han-2006" MODIFIED="2008-06-18 12:23:22 +0100" MODIFIED_BY="Hazel Fraser" NAME="Han 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-06-18 12:23:22 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Han JL, Wang HC, Yao XH</AU>
<TI>Therapeutic effect observation of Tongxinluo capsule for 30 cases of cerebral infarction</TI>
<SO>Clinical Journal of Difficult and Complicated Cases</SO>
<YR>2006</YR>
<VL>5</VL>
<NO>5</NO>
<PG>363</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hu-2002" MODIFIED="2008-06-18 12:23:39 +0100" MODIFIED_BY="Hazel Fraser" NAME="Hu 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-06-18 12:23:39 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hu H, Cao ZQ</AU>
<TI>80 cases of Tongxinluo capsule for stroke</TI>
<SO>Chinese Folk Therapy</SO>
<YR>2002</YR>
<VL>10</VL>
<NO>1</NO>
<PG>40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jia-2001" MODIFIED="2008-05-30 14:37:47 +0100" MODIFIED_BY="Hazel Fraser" NAME="Jia 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-05-30 14:37:47 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Jia W, Zhang M</AU>
<TI>Effect of tongxinluo capsule for stroke</TI>
<SO>Luobing theory of Chinese medicine and cardio-cerebral angiopathy</SO>
<YR>2001</YR>
<PG>286-7</PG>
<EN>1st</EN>
<ED>Wu YL</ED>
<PB>Chinese Science and Technical Publish House</PB>
<CY>Beijing</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2001" MODIFIED="2008-05-30 14:38:10 +0100" MODIFIED_BY="Hazel Fraser" NAME="Li 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-05-30 14:38:10 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Li YH, Chen J, Han X</AU>
<TI>Clinical observation of Tongxinluo capsule for acute stroke</TI>
<SO>Luobing theory of Chinese medicine and cardio-cerebral angiopathy</SO>
<YR>2001</YR>
<PG>306-8</PG>
<EN>1st</EN>
<ED>Wu YL</ED>
<PB>Chinese Science and Technical Publish House</PB>
<CY>Beijing</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2001" MODIFIED="2008-05-30 14:38:20 +0100" MODIFIED_BY="Hazel Fraser" NAME="Liu 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-05-30 14:38:20 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Liu L, Zhou HY</AU>
<TI>Clinical observation of Tongxinluo capsule for acute stroke</TI>
<SO>Luobing theory of Chinese medicine and cardio-cerebral angiopathy</SO>
<YR>2001</YR>
<PG>302-3</PG>
<EN>1st</EN>
<ED>Wu YL</ED>
<PB>Chinese Science and Technical Publish House</PB>
<CY>Beiing</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2001b" MODIFIED="2008-05-30 14:38:47 +0100" MODIFIED_BY="Hazel Fraser" NAME="Liu 2001b" YEAR="2001">
<REFERENCE MODIFIED="2008-05-30 14:38:47 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Liu WZ, Zheng MY, Gu YL, Hu JW</AU>
<TI>30 cases of Tongxinluo capsule for acute stroke</TI>
<SO>Luobing theory of Chinese medicine and cardio-cerebral angiopathy</SO>
<YR>2001</YR>
<PG>309-11</PG>
<EN>1st</EN>
<ED>Wu YL</ED>
<PB>Chinese Science and Technical Publish House</PB>
<CY>Beijing</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2001c" MODIFIED="2008-05-30 14:39:08 +0100" MODIFIED_BY="Hazel Fraser" NAME="Liu 2001c" YEAR="2001">
<REFERENCE MODIFIED="2008-05-30 14:39:08 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Liu RM</AU>
<TI>Observation of tongxinluo capsule for acute stroke</TI>
<SO>Luobing theory of Chinese medicine and cardio-cerebral angiopathy</SO>
<YR>2001</YR>
<PG>303-4</PG>
<EN>1st</EN>
<ED>Wu YL</ED>
<PB>Chinese Science and Technical Publish House</PB>
<CY>Beijing</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lu-2001" MODIFIED="2008-05-30 14:39:27 +0100" MODIFIED_BY="Hazel Fraser" NAME="Lu 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-05-30 14:39:27 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Lu B, Han L</AU>
<TI>Clinical research of Tongxinluo capsule for acute stroke</TI>
<SO>Luobing theory of Chinese medicine and cardio-cerebral angiopathy</SO>
<YR>2001</YR>
<PG>313</PG>
<EN>1st</EN>
<ED>Wu YL</ED>
<PB>Chinese Science and Technical Publish House</PB>
<CY>Beijing</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lu-2002" MODIFIED="2008-05-30 14:44:50 +0100" MODIFIED_BY="Hazel Fraser" NAME="Lu 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-05-30 14:44:50 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lu K</AU>
<TI>Therapeutic effect observation of Tongxinluo capsule for 62 cases of acute cerebral infarction</TI>
<SO>Medical Journal of CASC</SO>
<YR>2002</YR>
<VL>4</VL>
<NO>1</NO>
<PG>50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-2000" MODIFIED="2008-06-18 15:35:39 +0100" MODIFIED_BY="Hazel Fraser" NAME="Sun 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-06-18 15:35:39 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sun YS, Lin MS, Zhao L</AU>
<TI>Therapeutic effect evaluation of Tongxinluo capsule for ischaemic cerebrovascular diseases</TI>
<SO>Chinese Journal of Basic Medicine</SO>
<YR>2000</YR>
<VL>6</VL>
<NO>1</NO>
<PG>50-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2001" MODIFIED="2008-06-18 15:36:16 +0100" MODIFIED_BY="Hazel Fraser" NAME="Wang 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-06-18 15:36:16 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Wang SQ</AU>
<TI>Observation of ninety cases about Tongxinluo capsule for acute stroke</TI>
<SO>Luobing theory of Chinese medicine and cardio-cerebral angiopathy</SO>
<YR>2001</YR>
<PG>294-5</PG>
<EN>1st</EN>
<ED>Wu YL</ED>
<PB>Chinese Science and Technical Publish House</PB>
<CY>Beijing</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2006b" MODIFIED="2008-07-02 13:19:29 +0100" MODIFIED_BY="Hazel Fraser" NAME="Wang 2006b" YEAR="2006">
<REFERENCE MODIFIED="2008-07-02 13:19:29 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang YL</AU>
<TI>Clinical observation of tongxiluo in the treatment of stroke with "qixu xueyu luozhu" signs</TI>
<SO>Hubei Journal of Traditional Chinese Medicine</SO>
<YR>2006</YR>
<VL>28</VL>
<NO>4</NO>
<PG>34-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-2001" MODIFIED="2008-07-02 13:17:14 +0100" MODIFIED_BY="Hazel Fraser" NAME="Wu 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-07-02 13:17:14 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Wu YM</AU>
<TI>Observation of Tongxinluo capsule for stroke</TI>
<SO>Luobing theory of Chinese medicine and cardio-cerebral angiopathy</SO>
<YR>2001</YR>
<PG>314</PG>
<EN>1st</EN>
<ED>Wu YL</ED>
<PB>Chinese Science and Technical Publish House</PB>
<CY>Beijing</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xu-2001" MODIFIED="2008-06-18 12:26:47 +0100" MODIFIED_BY="Hazel Fraser" NAME="Xu 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-06-18 12:26:47 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Xu YM, Han F</AU>
<TI>Observation and analysis of Tongxinluo capsule for acute stroke</TI>
<SO>Luobing theory of Chinese medicine and cardio-cerebral angiopathy</SO>
<YR>2001</YR>
<PG>270-3</PG>
<EN>1st</EN>
<ED>Wu YL</ED>
<PB>Chinese Science and Technical Publish House</PB>
<CY>Beijing</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xu-2001b" MODIFIED="2008-06-18 12:26:35 +0100" MODIFIED_BY="Hazel Fraser" NAME="Xu 2001b" YEAR="2001">
<REFERENCE MODIFIED="2008-06-18 12:26:35 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Xu ZQ, Jiang XJ, Li JT</AU>
<TI>The effect of Tongxinluo capsule for stroke</TI>
<SO>Luobing theory of Chinese medicine and cardio-cerebral angiopathy</SO>
<YR>2001</YR>
<PG>315</PG>
<EN>1st</EN>
<ED>Wu YL</ED>
<PB>Chinese Science and Technical Publish House</PB>
<CY>Beijing</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xu-2003" MODIFIED="2008-06-18 15:36:35 +0100" MODIFIED_BY="Hazel Fraser" NAME="Xu 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-06-18 15:36:35 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xu YM, Ruan SC, Liu L, Zheng HB, Luo ZM</AU>
<TI>Effects of Tongxinluo capsule on neurological impairment and activity of daily life in acute cerebral infarction</TI>
<SO>Chinese Journal of Clinical Rehabilitation</SO>
<YR>2003</YR>
<VL>7</VL>
<NO>19</NO>
<PG>2709-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2001" MODIFIED="2008-07-02 13:17:43 +0100" MODIFIED_BY="Hazel Fraser" NAME="Yang 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-07-02 13:17:43 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Yang ZY, Qian YL</AU>
<TI>Observation of Tongxinluo capsule for stroke</TI>
<SO>Luobing theory of Chinese medicine and cardio-cerebral angiopathy</SO>
<YR>2001</YR>
<PG>291-3</PG>
<EN>1st</EN>
<ED>Wu YL</ED>
<PB>Chinese Science and Technical Publish House</PB>
<CY>Beijing</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2001" MODIFIED="2008-06-18 12:27:27 +0100" MODIFIED_BY="Hazel Fraser" NAME="Zhang 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-06-18 12:27:27 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Zhang JC</AU>
<TI>30 cases about Tongxinluo capsule for acute stroke</TI>
<SO>Luobing theory of Chinese medicine and cardio-cerebral angiopathy</SO>
<YR>2001</YR>
<PG>278-9</PG>
<EN>1st</EN>
<ED>Wu YL</ED>
<PB>Chinese Science and Technical Publish House</PB>
<CY>Beijing</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2001b" MODIFIED="2008-07-02 13:18:01 +0100" MODIFIED_BY="Hazel Fraser" NAME="Zhang 2001b" YEAR="">
<REFERENCE MODIFIED="2008-07-02 13:18:01 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Zhang JX, Zhu JG, Yuan DC, Li ZM, Wu Y, Wang HY</AU>
<TI>Observation of Tongxinluo capsule for acute stroke</TI>
<SO>Luobing theory of Chinese medicine and cardio-cerebral angiopathy</SO>
<YR>2001</YR>
<PG>317</PG>
<EN>1st</EN>
<ED>Wu YL</ED>
<PB>Chinese Science and Technical Publish House</PB>
<CY>Beijing</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2002" NAME="Zhang 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang WY, Yang HP</AU>
<TI>25 cases of Tongxinluo capsule for stroke</TI>
<SO>Journal of practical traditional Chinese medicine</SO>
<YR>2002</YR>
<VL>18</VL>
<NO>9</NO>
<PG>10-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhou-2004" NAME="Zhou 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhou SN, Zhou GY, Liu LQ</AU>
<TI>Therapeutic effects of tongxinluo capsule on patients with acute small cerebral infarction and its influence on SPECT brain perfusion image</TI>
<SO>Chinese Journal of Integrative Medicine</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>2</NO>
<PG>107-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhou-2005" MODIFIED="2008-06-18 12:28:33 +0100" MODIFIED_BY="Hazel Fraser" NAME="Zhou 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-06-18 12:28:33 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhou SN, Zhou GY, Liu LQ</AU>
<TI>Therapeutic effects of tongxinluo capsule on patients with acute small cerebral infarction and its influence on SPECT brain perfusion image</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>2005</YR>
<VL>Suppl 1</VL>
<PG>238</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2008-05-30 14:45:41 +0100" MODIFIED_BY="Hazel Fraser">
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2001b" MODIFIED="2008-05-30 14:45:41 +0100" MODIFIED_BY="Hazel Fraser" NAME="Wang 2001b" YEAR="2001">
<REFERENCE MODIFIED="2008-05-30 14:45:41 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Wang DH, Xi MH, Shi Y</AU>
<TI>Observation of tongxinluo capsule for acute stroke</TI>
<SO>Luobing theory of Chinese medicine and cardio-cerebral angiopathy</SO>
<YR>2001</YR>
<PG>281-2</PG>
<EN>1st</EN>
<ED>Wu YL</ED>
<PB>Chinese Science and Technical Publish House</PB>
<CY>Beijing</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-07-04 14:24:52 +0100" MODIFIED_BY="Hazel Fraser">
<ADDITIONAL_REFERENCES MODIFIED="2008-07-04 14:24:52 +0100" MODIFIED_BY="Hazel Fraser">
<REFERENCE ID="REF-Algra-1996" MODIFIED="2008-06-18 12:30:32 +0100" MODIFIED_BY="Hazel Fraser" NAME="Algra 1996" TYPE="JOURNAL_ARTICLE">
<AU>Algra A, van Gijn J</AU>
<TI>Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia after cerebral ischaemia</TI>
<SO>Journal of Neurology Neurosurgery and Psychiatry</SO>
<YR>1996</YR>
<VL>60</VL>
<PG>197-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-APT-1994" MODIFIED="2008-06-18 12:32:25 +0100" MODIFIED_BY="Hazel Fraser" NAME="APT 1994" TYPE="JOURNAL_ARTICLE">
<AU>Antiplatelet Trialists' Collaboration</AU>
<TI>Collaborative overview of randomised trials of antiplatelettherapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>308</VL>
<PG>81-106</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bamford-1990" MODIFIED="2008-06-18 12:32:40 +0100" MODIFIED_BY="Hazel Fraser" NAME="Bamford 1990" TYPE="JOURNAL_ARTICLE">
<AU>Bamford J, Sandercock P, Dennis M, Burn J, Warlow C</AU>
<TI>The frequency, causes and timing of death within 30 days of a first stroke: the Oxfordshire Community Stroke Project</TI>
<SO>Journal of Neurology, Neurosurgery and Psychiatry</SO>
<YR>1990</YR>
<VL>53</VL>
<PG>824-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Broderick-1989" MODIFIED="2008-06-18 12:33:07 +0100" MODIFIED_BY="Hazel Fraser" NAME="Broderick 1989" TYPE="JOURNAL_ARTICLE">
<AU>Broderick JP, Phillips SJ, Whisnant JP, O'Fallon WM, Bergstralh MS</AU>
<TI>Incidence rates of stroke in the eighties: the end of the decline in stroke?</TI>
<SO>Stroke</SO>
<YR>1989</YR>
<VL>20</VL>
<PG>577-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chen-1985" NAME="Chen 1985" TYPE="JOURNAL_ARTICLE">
<AU>Chen CY</AU>
<TI>Effect of Scolopendra extraction in the experiment of rabbit heart</TI>
<SO>Chinese Medicine Pharmacology and Clinical Practice</SO>
<YR>1985</YR>
<VL>1</VL>
<NO>1</NO>
<PG>124-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deng-1991" MODIFIED="2008-05-30 14:46:58 +0100" MODIFIED_BY="Hazel Fraser" NAME="Deng 1991" TYPE="JOURNAL_ARTICLE">
<AU>Deng CQ</AU>
<TI>Effect of Radix Paeoniae Rubra water-extraction in the experiment of anticoagulation</TI>
<SO>Chinese Medicine Pharmacology and Clinical Practice</SO>
<YR>1991</YR>
<VL>7</VL>
<NO>1</NO>
<PG>20-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Editor-2002" MODIFIED="2008-06-18 12:34:04 +0100" MODIFIED_BY="Hazel Fraser" NAME="Editor 2002" TYPE="OTHER">
<AU>Editor's note</AU>
<TI>An important new theory on Chinese herbal medicine for treatment of cardio-cerebral vascular diseases</TI>
<SO>China Medical Tribune</SO>
<YR>2002</YR>
<VL>28</VL>
<NO>24</NO>
<PG>16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2008-07-04 14:23:49 +0100" MODIFIED_BY="Hazel Fraser" NAME="Higgins 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]</TI>
<SO>The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Homer-1987" MODIFIED="2008-06-18 12:35:38 +0100" MODIFIED_BY="Hazel Fraser" NAME="Homer 1987" TYPE="JOURNAL_ARTICLE">
<AU>Homer D, Whisnant JP, Schoenberg BS</AU>
<TI>Trends in the incidence rates of stroke in Rochester, Minnesota, since 1935</TI>
<SO>Annals of Neurology</SO>
<YR>1987</YR>
<VL>22</VL>
<PG>245-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-IST-Pilot-1996" MODIFIED="2008-06-18 12:35:56 +0100" MODIFIED_BY="Hazel Fraser" NAME="IST Pilot 1996" TYPE="JOURNAL_ARTICLE">
<AU>international Stroke Trial Pilot Study Collaborative Group</AU>
<TI>Study design of the International Stroke Trial (IST), baseline data, and outcome in 984 randomised patients in the pilot study</TI>
<SO>Journal of Neurology Neurosurgery &amp; Psychiatry</SO>
<YR>1996</YR>
<VL>60</VL>
<PG>371-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liu-1997" MODIFIED="2008-06-18 12:36:22 +0100" MODIFIED_BY="Hazel Fraser" NAME="Liu 1997" TYPE="JOURNAL_ARTICLE">
<AU>Liu JX, Shang XH, Wang G, Zhang SC, Gao XD</AU>
<TI>Effect of Tongxinluo capsule on experimental myocardial ischemia, arrhythmia and hyperlipidemia</TI>
<SO>Chinese Journal of Integrated Traditional and Western Medicine</SO>
<YR>1997</YR>
<VL>17</VL>
<NO>7</NO>
<PG>425-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lu-1983" MODIFIED="2008-06-18 15:38:38 +0100" MODIFIED_BY="Hazel Fraser" NAME="Lu 1983" TYPE="JOURNAL_ARTICLE">
<AU>Lu EW, Zhao DZ, Wang R, Wang ML, Zhou X</AU>
<TI>Effect of Radix Paeoniae Rubrasin in the experiment on hyperlipidemia and hypercholesterolemia mice</TI>
<SO>Journal of Integrated Traditional and Western Medicine</SO>
<YR>1983</YR>
<VL>3</VL>
<NO>2</NO>
<PG>109-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nong-1989" NAME="Nong 1989" TYPE="JOURNAL_ARTICLE">
<AU>Nong ZJ, Shen YY, Dong HC</AU>
<TI>The effect of Eupolyphaga Sinensis Walk alkaloids on rabbits cardial pump function</TI>
<SO>Journal of Anhui Traditional Chinese Medical College</SO>
<YR>1989</YR>
<VL>8</VL>
<NO>3</NO>
<PG>84-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ou-1987" MODIFIED="2008-06-18 12:36:55 +0100" MODIFIED_BY="Hazel Fraser" NAME="Ou 1987" TYPE="JOURNAL_ARTICLE">
<AU>Ou XC, Ding JX, Zhang N</AU>
<TI>Experimental survey of 126 Chinese medicine antithrombin function</TI>
<SO>Chinese Traditional and Herbal Drugs</SO>
<YR>1987</YR>
<VL>18</VL>
<NO>4</NO>
<PG>21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pharmacology-1960" MODIFIED="2008-06-18 12:33:45 +0100" MODIFIED_BY="Hazel Fraser" NAME="Pharmacology 1960" TYPE="JOURNAL_ARTICLE">
<AU>Department of Pharmacology</AU>
<TI>Study of pharmacological of Periostracum Cicadae</TI>
<SO>Journal of Zhejiang Medical College</SO>
<YR>1960</YR>
<VL>3</VL>
<PG>93-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sandercock-1992" MODIFIED="2008-07-01 17:41:34 +0100" MODIFIED_BY="[Empty name]" NAME="Sandercock 1992" TYPE="CONFERENCE_PROC">
<AU>Sandercock P, Celani MG, Ricci S</AU>
<TI>The likely public health impact of simple treatments for acute ischaemic stroke</TI>
<SO>2nd European Stroke Conference</SO>
<YR>1992</YR>
<PG>25-27</PG>
<CY>Lausanne, Switzerland</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stanford-1999" MODIFIED="2008-06-18 12:38:51 +0100" MODIFIED_BY="Hazel Fraser" NAME="Stanford 1999" TYPE="OTHER">
<TI>Understanding stroke</TI>
<SO>http://www.stanford.edu/group/neurology/stroke/part1.html</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wang-1998" MODIFIED="2008-06-18 12:39:59 +0100" MODIFIED_BY="Hazel Fraser" NAME="Wang 1998" TYPE="BOOK">
<AU>Wang YS, Deng WL, Xue CS</AU>
<SO>Pharmacology and applications of Chinese Materia Medica</SO>
<YR>1998</YR>
<EN>2nd</EN>
<ED>People Health Publish House</ED>
<PB>Beijing</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wardlaw-2003" MODIFIED="2008-06-18 12:40:09 +0100" MODIFIED_BY="Hazel Fraser" NAME="Wardlaw 2003" TYPE="JOURNAL_ARTICLE">
<AU>Wardlaw JM, Warlow CP</AU>
<TI>Thrombolysis in acute ischaemic stroke - does it work?</TI>
<SO>Stroke</SO>
<YR>2003</YR>
<VL>23</VL>
<PG>1826-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wu-1994" NAME="Wu 1994" TYPE="JOURNAL_ARTICLE">
<AU>Wu JB, Liu HB, Lu WH, Lu YW, Wang Q</AU>
<TI>Comparison of adjustment function of three Hirudo products</TI>
<SO>Chinese Journal of Traditional Medicine</SO>
<YR>1994</YR>
<VL>19</VL>
<NO>6</NO>
<PG>343-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wu-2007" MODIFIED="2008-06-18 12:40:29 +0100" MODIFIED_BY="Hazel Fraser" NAME="Wu 2007" TYPE="JOURNAL_ARTICLE">
<AU>Wu B, Liu M, Liu H, Li W, Tan S, Zhang S, et al</AU>
<TI>Meta-analysis of traditional Chinese patent medicine for ischemic stroke</TI>
<SO>Stroke</SO>
<YR>2007</YR>
<VL>38</VL>
<NO>6</NO>
<PG>1973-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Xu-1988a" MODIFIED="2008-06-18 15:39:14 +0100" MODIFIED_BY="Hazel Fraser" NAME="Xu 1988a" TYPE="JOURNAL_ARTICLE">
<AU>Xu YJ</AU>
<TI>Effect of inhibition platelet adhesion reaction of Radix Ginseng</TI>
<SO>Journal of Pharmacology</SO>
<YR>1988</YR>
<VL>23</VL>
<NO>5</NO>
<PG>284-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Xu-1988b" MODIFIED="2008-06-18 12:41:42 +0100" MODIFIED_BY="Hazel Fraser" NAME="Xu 1988b" TYPE="JOURNAL_ARTICLE">
<AU>Xu JJ, Huang JM, Chen XH, Mong QD</AU>
<TI>Affection of Hirudo water-extraction for mice and human platelet adhesion reaction and blood rheology</TI>
<SO>Chinese Traditional Medicine Pharmacology and Clinical Practice</SO>
<YR>1988</YR>
<VL>4</VL>
<NO>4</NO>
<PG>35-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yang-1989" NAME="Yang 1989" TYPE="JOURNAL_ARTICLE">
<AU>Yang YF, Wang QM, Wang MH, Su XL, Yu ZQ</AU>
<TI>The effect of Eupolyphaga Sinensis Walk alkaloids on animal tolerance of hypoxia</TI>
<SO>Chinese Traditional Herbal Drags</SO>
<YR>1989</YR>
<VL>20</VL>
<NO>6</NO>
<PG>260-1</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2008-06-18 12:45:53 +0100" MODIFIED_BY="Hazel Fraser">
<REFERENCE ID="REF-Zhou-2004" MODIFIED="2008-06-18 12:45:53 +0100" MODIFIED_BY="Hazel Fraser" NAME="Zhou 2004" TYPE="COCHRANE_REVIEW">
<AU>Zhou L, Wu T, Duan X, Liu G, Qiao J</AU>
<TI>Tongxinluo capsule for acute stroke (Protocol)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-06-18 12:45:34 +0100" MODIFIED_BY="Hazel Fraser">
<IDENTIFIER MODIFIED="2008-06-18 12:45:34 +0100" MODIFIED_BY="Hazel Fraser" TYPE="DOI" VALUE="Art. No.: CD004584. DOI: 10.1002/14651858.CD004584"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-06-18 15:34:38 +0100" MODIFIED_BY="Hazel Fraser">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-06-18 15:34:38 +0100" MODIFIED_BY="Hazel Fraser" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-06-18 15:34:29 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Ding-2004">
<CHAR_METHODS MODIFIED="2008-05-30 14:30:02 +0100" MODIFIED_BY="Hazel Fraser">
<P>Design: randomised allocation was mentioned<BR/>Randomisation procedure: unclear<BR/>Blinding: not mentioned<BR/>Duration: 4 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-06-18 11:58:34 +0100" MODIFIED_BY="Hazel Fraser">
<P>120 participants all diagnosed as cerebral infarction based on head MRI or CT, and in accordance with the diagnosis criteria formulated at the 4th Chinese National Symposium on Cerebrovascular Diseases<BR/>Tongxinluo group: 62 participants (male/female: 40/22, age: 35 to 76 years, mean age: 64.12 years)<BR/>Control group: 58 participants (male/female: 38/20, age: 38 to 75 years, mean age 61.28 years)<BR/>Baseline neurological impairment similar between two groups (data unavailable)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-06-18 12:05:24 +0100" MODIFIED_BY="Hazel Fraser">
<P>Tongxinluo group: 4 tongxinluo capsules, tid for 4 weeks, and other basic treatment (unavailable)<BR/>Control group: the same basic treatment as tongxinluo group (unavailable)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-06-18 15:34:29 +0100" MODIFIED_BY="Hazel Fraser">
<P>Neurological impairment and daily living capability improvement based on Chinese national therapeutic effect evaluation criteria:<BR/>(1) cure<BR/>(2) marked improvement<BR/>(3) general improvement<BR/>(4) no improvement<BR/>(5) exacerbation<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-06-18 12:05:36 +0100" MODIFIED_BY="Hazel Fraser">
<P>The quality of this study is rated as C category</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-06-18 15:34:38 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Wang-2006">
<CHAR_METHODS MODIFIED="2008-05-30 14:31:21 +0100" MODIFIED_BY="Hazel Fraser">
<P>Design: randomised allocation was mentioned<BR/>Randomisation procedure: unclear.<BR/>Blinding: not mentioned<BR/>Duration: 2 weeks<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-06-18 12:07:04 +0100" MODIFIED_BY="Hazel Fraser">
<P>112 participants all diagnosed as cerebral infarction based on head MRI or CT, and in accordance with the diagnosis criteria formulated at the 4th Chinese National Symposium on Cerebrovascular Diseases. The onset is within 30 minutes and 48 hours before admission into hospital<BR/>Tongxinluo group: 56 participants (male/female: 34/22, age: 42 to 83 years, mean age 62.31 +/- 10.05 years)<BR/>Control group: 56 participants (male/female: 32/24, age: 41 to 80 years, mean age 61.64 +/- 9.87 years)<BR/>Baseline neurological impairment similar between two groups (data unavailable)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-06-18 12:07:26 +0100" MODIFIED_BY="Hazel Fraser">
<P>Tongxinluo group: 3 tongxinluo capsules, tid for two weeks, low-molecular heparin, mannitol, citicoline<BR/>Control group: low-molecular heparin, mannitol, citicoline</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-06-18 15:34:38 +0100" MODIFIED_BY="Hazel Fraser">
<P>Neurological impairment and daily living capability improvement based on Chinese national therapeutic effect evaluation criteria and the Modified Edinburgh-Scandinavian Stroke Scale:<BR/>(1) cure<BR/>(2) marked improvement<BR/>(3) general improvement<BR/>(4) no improvement<BR/>(5) exacerbation<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-06-18 12:09:49 +0100" MODIFIED_BY="Hazel Fraser">
<P>The quality of this study is rated as C category</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>CT: computerised tomography<BR/>MRI: magnetic resonance imaging<BR/>tid: three times per day </P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-06-18 12:13:16 +0100" MODIFIED_BY="Hazel Fraser" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2008-05-30 14:31:52 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Cai-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-30 14:31:52 +0100" MODIFIED_BY="Hazel Fraser">
<P>Randomisation was not mentioned in the study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-30 14:31:53 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Chen-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-30 14:31:53 +0100" MODIFIED_BY="Hazel Fraser">
<P>Randomisation was not mentioned in the study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-30 14:32:19 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Ding-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-30 14:32:19 +0100" MODIFIED_BY="Hazel Fraser">
<P>We contacted and interviewed the original author only to find that the trial was actually a retrospective trial with no research protocol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-06-18 12:13:16 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Fan--2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-06-18 12:13:16 +0100" MODIFIED_BY="Hazel Fraser">
<P>Confounded trial as control group used so-called positive effect drugs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-30 14:32:36 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Gu-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-30 14:32:36 +0100" MODIFIED_BY="Hazel Fraser">
<P>We contacted and interviewed the original author only to find that the trial was actually a quasi-randomised trial with no blinding</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-30 14:32:46 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Han-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-30 14:32:46 +0100" MODIFIED_BY="Hazel Fraser">
<P>We contacted and interviewed the original author only to find that the trial was actually a quasi-randomised trial with no blinding</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-30 14:32:56 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Hu-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-30 14:32:56 +0100" MODIFIED_BY="Hazel Fraser">
<P>We contacted and interviewed the original author only to find that the trial was actually a quasi-randomised trial with no blinding</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-30 14:33:37 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Jia-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-30 14:33:37 +0100" MODIFIED_BY="Hazel Fraser">
<P>Non-randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-06-18 12:11:22 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Li-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-06-18 12:11:22 +0100" MODIFIED_BY="Hazel Fraser">
<P>Confounded trial as control group used so-called positive effect drugs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-06-18 12:11:25 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Liu-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-06-18 12:11:25 +0100" MODIFIED_BY="Hazel Fraser">
<P>Confounded trial as control group used so-called positive effect drugs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-06-18 12:11:29 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Liu-2001b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-06-18 12:11:29 +0100" MODIFIED_BY="Hazel Fraser">
<P>Confounded trial as control group used so-called positive effect drugs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-30 14:33:10 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Liu-2001c">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-30 14:33:10 +0100" MODIFIED_BY="Hazel Fraser">
<P>Randomisation was not mentioned in the study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-06-18 12:11:38 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Lu-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-06-18 12:11:38 +0100" MODIFIED_BY="Hazel Fraser">
<P>Confounded trial as control group used so-called positive effect drugs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-30 14:33:25 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Lu-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-30 14:33:25 +0100" MODIFIED_BY="Hazel Fraser">
<P>We contacted and interviewed the original author only to find that the trial was actually a non-randomised trial with no blinding</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-30 14:33:49 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Sun-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-30 14:33:49 +0100" MODIFIED_BY="Hazel Fraser">
<P>We contacted and interviewed the original author only to find that the trial was actually a retrospective trial with no research protocol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-06-18 12:11:53 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Wang-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-06-18 12:11:53 +0100" MODIFIED_BY="Hazel Fraser">
<P>Confounded trial as control group used so-called positive effect drugs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-06-18 12:12:05 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Wang-2006b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-06-18 12:12:05 +0100" MODIFIED_BY="Hazel Fraser">
<P>This study aims to compare the effect of tongxinluo capsule versus danshen</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-30 14:34:05 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Wu-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-30 14:34:05 +0100" MODIFIED_BY="Hazel Fraser">
<P>The whole study was not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-30 14:34:13 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Xu-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-30 14:34:13 +0100" MODIFIED_BY="Hazel Fraser">
<P>Non-randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-30 14:34:18 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Xu-2001b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-30 14:34:18 +0100" MODIFIED_BY="Hazel Fraser">
<P>Non-randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-30 14:34:29 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Xu-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-30 14:34:29 +0100" MODIFIED_BY="Hazel Fraser">
<P>We contacted and interviewed the original author only to find that the trial was actually a retrospective trial with no research protocol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yang-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Quasi-randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-06-18 12:12:24 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Zhang-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-06-18 12:12:24 +0100" MODIFIED_BY="Hazel Fraser">
<P>Confounded trial as control group used so-called positive effect drugs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-30 14:34:35 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Zhang-2001b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-30 14:34:35 +0100" MODIFIED_BY="Hazel Fraser">
<P>The whole study was not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-30 14:34:44 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Zhang-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-30 14:34:44 +0100" MODIFIED_BY="Hazel Fraser">
<P>We contacted and interviewed the original author only to find that the trial was actually a retrospective trial with no research protocol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-06-18 12:12:40 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Zhou-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-06-18 12:12:40 +0100" MODIFIED_BY="Hazel Fraser">
<P>Quasi-randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-06-18 12:12:43 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Zhou-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-06-18 12:12:43 +0100" MODIFIED_BY="Hazel Fraser">
<P>Quasi-randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-Wang-2001b">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-06-18 12:20:07 +0100" MODIFIED_BY="Hazel Fraser">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-06-18 12:20:07 +0100" MODIFIED_BY="Hazel Fraser" NO="1">
<TITLE MODIFIED="2008-06-18 12:14:37 +0100" MODIFIED_BY="Hazel Fraser">Composition of tongxinluo</TITLE>
<TABLE COLS="4" ROWS="9">
<TR>
<TH>
<P>Latin name</P>
</TH>
<TH>
<P>Common name</P>
</TH>
<TH>
<P>Pharmacological actions</P>
</TH>
<TH>
<P>Dosage proportion</P>
</TH>
</TR>
<TR>
<TD>
<P>Radix Ginseng</P>
</TD>
<TD>
<P>Ren shen</P>
</TD>
<TD>
<P>Strengthens cardiac contractility, increasing cardiac output, and has cardiokinetic function, slows heart rate down, dilates blood vessel, anticoagulation, inhibits platelet adhesion reaction</P>
</TD>
<TD>
<P>10% to 20%</P>
</TD>
</TR>
<TR>
<TD>
<P>Scorpio</P>
</TD>
<TD>
<P>Scorpion</P>
</TD>
<TD>
<P>Treatment of hypertension, apoplexy, arteriosclerosis, some nervous system diseases, various tumefaction and infections</P>
</TD>
<TD>
<P>10% to 20%</P>
</TD>
</TR>
<TR>
<TD>
<P>Hirudo</P>
</TD>
<TD>
<P>Leech</P>
</TD>
<TD>
<P>Anticoagulation, thrombolysis, reduces viscosity of whole blood, anti-myocardial ischaemia, induces cholesterol and anti-atherosclerosis</P>
</TD>
<TD>
<P>20% to 30%</P>
</TD>
</TR>
<TR>
<TD>
<P>Eupolyphaga seu Steleophage</P>
</TD>
<TD>
<P>Eupolyphaga sinensis walk, Ground beetle</P>
</TD>
<TD>
<P>Increases cardiac output, improves tolerance of hypoxia</P>
</TD>
<TD>
<P>10% to 20%</P>
</TD>
</TR>
<TR>
<TD>
<P>Scolopendra</P>
</TD>
<TD>
<P>Centipede</P>
</TD>
<TD>
<P>Strengthens cardiac contractility, decreases blood pressure, and increases blood vessel perfusion flow</P>
</TD>
<TD>
<P>6% to 15%</P>
</TD>
</TR>
<TR>
<TD>
<P>Periostracum Cicadae</P>
</TD>
<TD>
<P>Cicada slough</P>
</TD>
<TD>
<P>Anticonvulsive and slows heart rate down</P>
</TD>
<TD>
<P>10% to 20%</P>
</TD>
</TR>
<TR>
<TD>
<P>Radix Paeoniae Rubra</P>
</TD>
<TD>
<P>The root of common peony</P>
</TD>
<TD>
<P>Anticoagulation and prevents thrombosis functions, and inhibits formation of platelet and fibrin thrombus, dilates coronary artery directly, has a strong anti-myocardial ischaemia function, and changes the content of lipoprotein, deduces calcium ion sediments on the arterious parietes, anti-atherosclerosis</P>
</TD>
<TD>
<P>5% to 15%</P>
</TD>
</TR>
<TR>
<TD>
<P>Borneolum Syntheticum</P>
</TD>
<TD>
<P>Borneol</P>
</TD>
<TD>
<P>Analgesia and sedation</P>
</TD>
<TD>
<P>2% to 10%</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-05-30 14:26:37 +0100" MODIFIED_BY="Hazel Fraser">
<COMPARISON ID="CMP-001" MODIFIED="2008-05-30 14:26:37 +0100" MODIFIED_BY="Hazel Fraser" NO="1">
<NAME>Effects</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="99" EVENTS_2="65" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-05-30 14:26:37 +0100" MODIFIED_BY="Hazel Fraser" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="118" TOTAL_2="114" WEIGHT="0.0" Z="0.0">
<NAME>Improvement</NAME>
<GROUP_LABEL_1>Tongxinluo</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours tongxinluo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="1.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="99" EVENTS_2="65" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2008-05-30 14:26:37 +0100" MODIFIED_BY="Hazel Fraser" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="118" TOTAL_2="114" WEIGHT="0.0" Z="0.0">
<NAME>Tongxinluo capsule and other treatment vs other treatment</NAME>
<DICH_DATA CI_END="1.5630717857110104" CI_START="0.9819342219711807" EFFECT_SIZE="1.2388840453356582" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="37" LOG_CI_END="0.1939789239067505" LOG_CI_START="-0.00791760385434643" LOG_EFFECT_SIZE="0.09303066002620207" ORDER="2172" O_E="0.0" SE="0.11859501981079898" STUDY_ID="STD-Ding-2004" TOTAL_1="62" TOTAL_2="58" VAR="0.014064778723923803" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.356080092011144" CI_START="1.3534240712004622" EFFECT_SIZE="1.7857142857142858" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="28" LOG_CI_END="0.37219004966653535" LOG_CI_START="0.13143389632106384" LOG_EFFECT_SIZE="0.2518119729937996" ORDER="2173" O_E="0.0" SE="0.14142135623730953" STUDY_ID="STD-Wang-2006" TOTAL_1="56" TOTAL_2="56" VAR="0.020000000000000004" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>